Lavelle Erin
Insider CIK 1737613 · NLTX Director · ALDR Chief Operating Officer · AVLN Director · ELYM COO & CFO · JBIO Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 34,843 | — | $0 | 34,843 | SEC↗ |
| AVLN Avalyn Pharma Inc. | A Award deriv | 2026-04-30 | 2026-05-01 | 26,978 | — | $0 | 26,978 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2025-04-29 | 2025-05-01 | 23,017 | — | $0 | 23,017 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2023-06-08 | 2023-06-09 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award deriv | 2022-10-31 | 2022-11-02 | 170,000 | — | $0 | 170,000 | SEC↗ |
| NLTX Neoleukin Therapeutics, In | A Award deriv | 2022-05-12 | 2022-05-16 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award deriv | 2022-01-27 | 2022-01-31 | 170,000 | — | $0 | 170,000 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | D To issuer deriv | 2019-10-22 | 2019-10-24 | 150,000 | — | $0 | 0 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | D To issuer deriv | 2019-10-22 | 2019-10-24 | 300,000 | — | $0 | 0 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | U Tender | 2019-10-22 | 2019-10-24 | 16,092 | $18.00 | $289.7K | 0 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | A Award | 2019-10-22 | 2019-10-24 | 11,684 | — | $0 | 16,092 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | S Sale | 2019-04-25 | 2019-04-25 | 1,434 | $13.67 | $19.6K | 4,408 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | A Award | 2019-04-23 | 2019-04-25 | 5,842 | — | $0 | 5,842 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | A Award deriv | 2019-02-06 | 2019-02-08 | 150,000 | — | $0 | 150,000 | SEC↗ |
| ALDR ALDER BIOPHARMACEUTICALS I | A Award deriv | 2018-04-16 | 2018-04-18 | 300,000 | — | $0 | 300,000 | SEC↗ |